Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
In a phase 2 clinical trial, the oral, FGFR1-3 selective tyrosine kinase inhibitor, infigratinib correlated with promising anticancer activity in addition to manageable safety as treatment of patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.
The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.
Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.
In patients with esophageal cancer, chemotherapy with or without added pembrolizumab led to similar health-related quality of life results over 18 weeks, according to findings from the phase 3 KEYNOTE-590 study.
In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.